Anifrolumab denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for anifrolumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Issue a "Not FDA-Approved" Denial for Anifrolumab

This denial type usually reflects one of two scenarios: (1) the claim was coded in a way that made the use appear off-label — for example, a diagnosis code that does not match anifrolumab's approved indication — or (2) Cigna's automated claims system flagged the drug against an outdated policy that predates or does not yet reflect its approval status. In either case, this denial is correctable with proper documentation because anifrolumab does hold FDA approval for adults with moderate-to-severe active systemic lupus erythematosus (SLE) on standard therapy.

## Why This Denial Is Appealable

A denial asserting the drug is not FDA-approved is factually incorrect for SLE when the indication and patient population match the approval. Appeals on this basis succeed by presenting the FDA-approved prescribing label and confirming that the submitted diagnosis and patient population align exactly with that label.

## Your Federal Appeal Rights

• Internal appeal: Submit a written appeal immediately. For an administrative coding or approval-status error, this category of denial often resolves at the internal appeal stage when the correct documentation is provided.
• External review (ACA §2719): If the internal appeal is denied, independent external review is available. The reviewer will assess whether the denial was consistent with the evidence. An approval-status error is difficult for an insurer to defend at external review.
• Timeline: Request external review within approximately four months of the final internal denial. Expedited review is available for urgent cases.

## Documentation to Gather

1. FDA prescribing label for anifrolumab — print the current full prescribing information from the FDA website (Drugs@FDA). Highlight the approved indication section. 2. Diagnosis documentation — confirm the ICD-10 code submitted matches the approved indication. Rheumatologist notes confirming SLE diagnosis and classification. 3. Corrected claim or prior-auth resubmission — if the original submission used an incorrect diagnosis code, resubmit with the corrected code alongside the appeal. 4. Prescriber attestation — a brief letter from the rheumatologist confirming the patient has moderate-to-severe SLE consistent with the FDA-approved indication and that anifrolumab is being used on-label. 5. Cigna's denial rationale — obtain the specific policy language Cigna cited. If the policy is outdated, document the FDA approval date to demonstrate the policy does not reflect current regulatory status.

## Criteria-Mapping Structure

In your appeal, lead with the FDA approval fact and attach the label. Then map the patient's diagnosis and treatment context to the exact indication language in the label. If Cigna cited a specific coverage policy document, pull that policy and identify whether it has been updated since approval. Reviewers and external review organizations respond well to a concise factual correction supported by primary regulatory documents.